21 May 2013
Keywords: report, sees, fundamental, flaws, many, rx, studies
Article | 05 December 2005
Merck & Co's COX-2 inhibitor arthritis drug Vioxx (rofecoxib) eased the pain of millions of arthritis patients, but it also greatly ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 December 2005
19 December 2005
© 2013 thepharmaletter.com